This page shows the latest PRIME status news and features for those working in and with pharma, biotech and healthcare.
It has been given a breakthrough designation by the FDA, Priority Medicines (PRIME) status by the EMA and has been awarded a Promising Innovative Medicine (PIM) designation from the MHRA in
The EMA’s PRIME status offers enhanced interaction and early dialogue to help companies accelerate their development plans and speed up evaluation for cutting-edge therapies in areas of high unmet ... The PRIME status could help it close the gap on its
In Europe, MEDI8897 has been given PRIME status by the EMA, while the long-acting anti-RSV antibody has picked up a breakthrough designation from the FDA in the US. ... The FDA had already given the drug fast-track status, cutting its review time down to
PRIME status takes it one step closer to fruition, as it will give Roche additional support from the EMA as the company prepares and files risdiplam for approval in Europe. ... Only one in five drugs submitted for PRIME end up being awarded the status.
In Europe, emapalumab has been granted orphan designation and PRIME (PRIority MEdicine) status by the EMA, and has been filed for approval with a verdict due in 2019.
beta thalassaemia – which has just bagged a Priority Medicines (PRIME) designation from the EMA. ... Orchard is playing catch-up in thalassaemia with Bluebird Bio, which is planning to file its LentiGlobin candidate in Europe before the end of this year
More from news
Approximately 1 fully matching, plus 9 partially matching documents found.
Figure 1: Treatments with PRIME status by therapeutic area. Source: Analysis using EMA data after two years of PRIME. ... PRIME status is being touted as useful to help advance development of RG6042.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Communique Small consultancy of the year 2020. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC...